Oral mucositis in children with cancer and their relationship with limitation of activities
Miguel Á. Palomo-Colli 1, Diana Carolina Soltero-Becerril 2, Luis E. Juárez-Villegas 3, Carlo Cicero-Oneto 3, José F. Gaytán-Morales 3, Iván Castorena-Villa 3, Mónica Mier-Cabrera 1
1 Departamento de Hemato-Oncología, Unidad de Hemato-Oncología e Investigación, Hospital Infantil de México Federico Gómez, Ciudad de México, México; 2 Departamento de Pediatría Médica. Hospital Infantil de México Federico Gómez, Ciudad de México, México; 3 Departamento de Oncología, Hospital Infantil de México Federico Gómez, Ciudad de México, México
Miguel Á. Palomo-Colli, Diana Carolina Soltero-Becerril, Luis E. Juárez-Villegas, Carlo Cicero-Oneto, José F. Gaytán-Morales, Iván Castorena-Villa, Mónica Mier-Cabrera
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondencia: Carlo Cicero-Oneto, Email no disponible
Resumen
Introduction: Oral mucositis (OM) is a common chemo and radiotherapy adverse effect in oncological pediatric patients, oral complications may be observed during chemotherapy and are important side effects that may directly affect the anticancer treatment. Methods: We included 420 children and monitored them for 2 weeks after the initiation of chemotherapy between June 2012 and June 2016. Subjects were asked to use a daily diary to complete the related questions of the OM Daily Questionnaire from the start of chemotherapy to day 14. Results: Overall, 73% (n = 307) of paediatric patients developed OM. Most cases were Grade 2 and 3. Of these, 12% (n = 32) were Grade 1, and 49% (n = 205) Grade 2. The mean time to onset of OM was 4.5 (standard deviation [SD]: 2.5; range: 2-9; 95% confidence interval [CI]: 3.8-5.3) days after the start of chemotherapy, with a mean duration of 6.5 (SD: 4; range: 2-13; 95% CI: 5.2-9.4) days and with the peak at day 7.1 (SD: 2.8; range: 4-11; 95% CI: 6.8-8.4). Conclusions: OM is associated with negative effects on clinical outcomes.
